Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 3, 2026, Cohance Lifesciences announced two transactions to enhance its Antibody-Drug Conjugate (ADC) strategy. The company approved acquiring an additional 244,587 shares of NJ Bio, Inc. for approximately USD 13 million, increasing its stake from 56% to 67.3%. Additionally, it approved subscribing to Aruka Bio, Inc. shares for approximately USD 5 million to acquire a 65% controlling interest. Both investments are funded through internal accruals and were expected to be completed by the end of September 2026, subject to definitive agreements and regulatory approvals.
Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) held its 8th Annual General Meeting on September 17, 2026. Three ordinary resolutions were presented and passed with over 99.97% of votes in favor. These resolutions included the adoption of standalone and consolidated financial statements and the reappointment of Ms. Shweta Jalan as a director.
As of September 18, 2026, daily technical indicators suggest a mixed trend. The Supertrend indicator is 'bullish' at 413.34, while the 20-day Exponential Moving Average (EMA) is 444.67, and the 50-day EMA is 442.92. The closing price was ₹438.0. The Average Directional Index (ADX) is 29.03, indicating some trend strength, with Plus DI at 21.81 and Minus DI at 19.36.
As of September 18, 2026, Cohance Lifesciences' stock has experienced varied returns across different timeframes. It showed a positive return of 0.06 over 3 months and 0.43 over 6 months. However, it recorded negative returns of -0.04 over 1 month, -0.08 over 20 days, -0.05 over 10 days, -0.02 over 5 days, -0.16 year-to-date, and a significant -0.52 over the past year. The return since the start of trading was -0.59.
As of 18 Sept 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Downward price movement of 2.65 standard deviations recorded on 2026-08-12.
Unusual market activity that may warrant review of the underlying price, volume, or news context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹422.26 crore | ₹619.12 crore | ₹544.55 crore | PEAK₹1,104.88 crore | ₹549.31 crore |
| Finance Costs | ₹6.74 crore | ₹9.19 crore | ₹9.11 crore | PEAK₹18.94 crore | ₹10.18 crore |
| Other Expenses | ₹167.86 crore | ₹177 crore | ₹171.61 crore | PEAK₹322.61 crore | ₹155.84 crore |
| Profit Before Tax | -₹42.87 crore | ₹19.91 crore | ₹40.60 crore | PEAK₹146.53 crore | ₹62.76 crore |
| Tax Expense | ₹2.32 crore | ₹11.60 crore | ₹11.58 crore | PEAK₹33.74 crore | ₹16.36 crore |
| Profit Loss For Period | -₹45.19 crore | ₹8.31 crore | ₹29.02 crore | PEAK₹112.79 crore | ₹46.40 crore |
The quarter’s loss resulted from a sharp 23% year-on-year revenue decline to ₹422.26 crore, while other expenses rose 7.7% to ₹167.86 crore, expanding the other-expense-to-revenue ratio from 28.4% to 39.8%. The resulting pre-tax loss of ₹42.87 crore and net loss of ₹45.19 crore reversed the prior-year profit, with a tax expense further widening the net loss.
Exchange disclosures and regulatory announcements for Cohance Lifesciences.
Cohance Lifesciences Limited remitted USD 10 million to subscribe to 188,680 new Compulsorily Convertible Preferred Stocks (CCPS) of its subsidiary NJ Bio, Inc., at USD 53.00 per CCPS, following the board approval disclosed on December 2, 2025. The cash consideration was funded through internal accruals, and the transaction is expected to complete before the end of September 2026. NJ Bio, an ADC-focused CRDMO incorporated on October 23, 2017, reported turnover of USD 20.6 million (CY2023), USD 32.6 million (CY2024), and USD 23.5 million (CY2025). The investment, classified as a related party transaction at arm's length, supports NJ Bio's growth initiatives including capex, with the CCPS convertible to equity after 3 years.
Cohance Lifesciences Limited announced on 17 September 2026 that its management will attend the JP Morgan India Conference in Mumbai on 22 September 2026 and the JP Morgan Roadshow in Hyderabad on 24 September 2026. The company confirmed that no unpublished price-sensitive information will be shared during these group and one-on-one interactions, while noting that the schedule remains subject to change due to exigencies.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) held its 8th Annual General Meeting on 17 September 2026 via video conferencing, with 50 shareholders attending out of 97,424 on the cut-off date. The meeting transacted three ordinary resolutions: adoption of standalone and consolidated financial statements, and reappointment of Ms. Shweta Jalan as a director liable to retire by rotation. All resolutions were passed by the requisite majority, with over 99.97% of votes cast in favor for each item, as confirmed by the Scrutinizer's Report dated 17 September 2026.
Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection |SUBJECT: General Updates
On September 3, 2026, Cohance Lifesciences Limited's Investment, Banking and Authorisations Committee approved a reorganization involving two transactions: acquiring an additional 244,587 shares of NJ Bio, Inc. for approximately USD 13 million to increase its stake from 56% to 67.3%, and subscribing to Aruka Bio, Inc. shares for approximately USD 5 million to acquire a 65% controlling interest. Both investments are funded through internal accruals and are subject to definitive agreements and regulatory approvals, with completion expected by the end of September 2026.
Cohance Lifesciences announced two proposed transactions to strengthen its ADC strategy: an additional USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio, totaling USD 18 million funded through internal accruals. The investment will increase Cohance's ownership in NJ Bio from 56.0% to 67.3% by acquiring holdings from Ms. Priyashri Nayak and the Jain Family Irrevocable Trust, with Dr. Jain retaining 32.7%. Aruka Bio will become a direct subsidiary of Cohance, owned 65% directly by Cohance, 25% by NJ Bio, and 10% by Dr. Jain. Completion is expected by the end of September 2026, subject to definitive agreements and customary conditions.
Amber Enterprises India Limited, ASI Industries Limited, Cohance Lifesciences Limited, Eldeco Housing and Industries Limited, and CG Power and Industrial Solutions Limited have issued notices for their respective Annual General Meetings scheduled between September 16 and September 23, 2026, to be conducted exclusively via Video Conference. These filings confirm the dispatch of meeting notices and annual reports on August 25-26, 2026, and establish specific remote e-voting periods commencing in mid-September with cut-off dates ranging from September 7 to September 21, 2026. Additionally, CG Power announced a postal ballot on August 26, 2026, seeking shareholder approval for the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced that its management will attend the Ashwamedh - Elara India Dialogue 2026 conference in Mumbai on September 1, 2026. The scheduled interaction includes both group and one-on-one sessions with analysts and institutional investors, subject to potential changes due to exigencies. The company confirmed that no unpublished price-sensitive information will be disclosed during this event.
Recent market and company developments associated with Cohance Lifesciences.
Axis AMC, PMS, Alternates, Axis brokerage. portfolio management
Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, JSW Steel, Tata Motors, TMCV, Mazagon Dock Engineering, RVNL, Rail Vikas Nigam, Lupin, Molbio Diagnostics, Purple Style Labs, HEG, Lemon Tree Hotels, Shiprocket, Behari Lal Engineering, Mazagon Dock Shipbuilders, Lemon Tree Hotels, Cohance Lifesciences, Urban Enviro Waste Management, Brigade Enterprises, Price Focus, Nava, Jayaswal Neco Industries
Cohance Lifesciences invests $18 million in NJ Bio and Aruka Bio to enhance its antibody-drug conjugate strategy and partnerships.
Buzzing Stocks
IEX logs record August volumes; HEG renamed as scheme takes effect
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.
Umang Vohra, Cohance Lifesciences, Advent International, Advent, Suven Pharma, CDMO, API, Vivek Sharma, NJ Bio, ADCs
ICICI Securities, reduce, Cohance Lifesciences, Recommendation
Comprehensive Section Breakdown for Cohance Lifesciences
Strategic Vision: Global CDMO for pharmaceutical and chemical product lifecycles.
• Expertise in handling complex, sensitive, and high-potency APIs.
• Robust safety assessments and regulatory compliance.
• Extensive experience in nucleic acid chemistry and custom synthesis.
• Global regulatory expertise and a reliable supply network for generic APIs.
• Integration of scientific expertise, scalable manufacturing, and regulatory excellence in specialty chemicals.
Cohance Lifesciences reported its lowest quarterly revenue in recent periods, resulting in a shift from profit to loss for the quarter ended June 30, 2026. Revenue fell 23.1% year-over-year to ₹422.26 crore. While finance costs decreased slightly, other expenses rose 7.7% compared to the same period last year. This combination produced a pre-tax loss of ₹42.87 crore and a net loss of ₹45.19 crore, reversing the ₹46.40 crore profit recorded a year earlier. A tax expense of ₹2.32 crore during the loss-making quarter further widened the net loss.
Revenue from operations stood at ₹422.26 crore, a 31.8% decrease from the previous quarter (₹619.12 crore) and a 23.1% decrease from the year-ago quarter (₹549.31 crore). The quarterly data shows significant variability: the second quarter of the prior fiscal year recorded ₹1,104.88 crore, roughly double the surrounding quarters, while the current quarter represents the lowest point in the series. The sequential decline of ₹196.86 crore brought revenue to the bottom of the observed range.
Other expenses totaled ₹167.86 crore, a 7.7% increase from ₹155.84 crore in the year-ago quarter, even as revenue contracted. As a result, other expenses as a percentage of revenue expanded from 28.4% to 39.8%. Sequentially, other expenses declined 5.2% from ₹177.00 crore in the prior quarter, but this reduction was insufficient to offset the 31.8% drop in revenue. Finance costs decreased 26.7% sequentially to ₹6.74 crore, representing approximately 1.6% of revenue and providing only a minor offset to the profitability pressure.
Profit Before Tax swung from a profit of ₹19.91 crore in the preceding quarter to a loss of ₹42.87 crore. Compared to the year-ago quarter, PBT moved from a profit of ₹62.76 crore to a loss of ₹42.87 crore. Despite recording a pre-tax loss, the company recognized a tax expense of ₹2.32 crore, which increased the absolute size of the net loss to ₹45.19 crore. In the year-ago quarter, the effective tax rate was approximately 26%, and in the fourth quarter of the prior fiscal year, the tax-to-profit ratio exceeded 58%.
Basic Earnings Per Share moved from ₹1.28 in the year-ago quarter to a loss of ₹0.63. Diluted EPS followed a similar path, declining from ₹1.27 to a loss of ₹0.65. Paid-up equity share capital remained constant at ₹38.26 crore (face value ₹1 per share) across the reporting periods, indicating no equity issuances or buybacks occurred. The per-share loss reflects the consolidated earnings result, calculated using weighted average shares rather than a simple division of net loss by paid-up capital.
Cohance Lifesciences reported a weak Q1 FY27, as guided, with consolidated revenue down 23.1% YoY to ₹4,223 Mn and adjusted EBITDA of ₹92 Mn (2.2% margin), reflecting shipment phasing, negative operating leverage, and subsidiary consolidation. Management expects sequential improvement from Q2 and a return to year-on-year growth in H2 FY27, supported by secured orders, scheduled deliveries, and progress across the late-stage pipeline. Key strategic actions include building an integrated nucleic-acid business with a clear path to full ownership of Sapala and repositioning Agrochemicals towards an innovator-product-led portfolio. The API+ business remained resilient with a healthy order book, while the USFDA inspection at Pashamylaram concluded with five addressable observations, none related to data integrity. The balance sheet remains net cash positive at ₹2,512 Mn, with free cash flow of ₹1,063 Mn generated during the quarter.
Category: B2B Services
Offers end-to-end solutions for Small Molecule API development and manufacturing, from early-phase process design to commercial supply, handling complex and high-potency APIs.
Category: B2B Services
Provides custom nucleic acid synthesis, process development, scale-up, and GMP manufacturing for therapeutic companies developing drugs based on oligonucleotides and other emerging modalities.
Category: B2B Services
Operates an integrated Generic API platform serving a global customer base with over 50 molecules across various therapeutic areas, supported by 8 cGMP facilities.
Category: B2B Services
Delivers advanced solutions in Agrochemicals and Performance Chemicals, integrating scientific expertise, scalable manufacturing, and regulatory excellence for various industries.
Core Thesis: The company was formed through a strategic integration of several entities to bring together diverse capabilities across Pharma CDMO, APIs, Specialty Chemicals, and next-generation platforms.
• Integrated Solutions: Provides comprehensive, end-to-end solutions across the lifecycle of pharmaceutical and chemical products, from development to commercial supply. • Diverse Capabilities: Consolidates expertise in Pharma CDMO, APIs, Specialty Chemicals, Formulations, and advanced platforms like ADCs and Oligonucleotides. • Global Operations: Operates state-of-the-art facilities located in both India and the U.S. • Backward Integration: Maintains a fully backward-integrated supply chain to ensure quality, speed, and reliability.